Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clarithromycin and Rifampicin for Buruli Ulcer
NCT01659437Phase 3Completed
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2012
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, single-blind trial of clarithromycin in Buruli ulcer (BU), sponsored by University Medical Center Groningen. Primary endpoint: Healing without recurrence and without excision surgery at 12 months. Started Dec 2012; status: completed.
02
Drugs
clarithromycin
03
Conditions
Buruli ulcer (BU)
Beyond the preview
Go deeper on NCT01659437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01659437.